Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An open-label, parallel, multiple-dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers.
Morelli G, Chen H, Rossiter G, Rege B, Lu Y. Morelli G, et al. Among authors: rossiter g. Aliment Pharmacol Ther. 2011 Apr;33(7):845-54. doi: 10.1111/j.1365-2036.2011.04580.x. Epub 2011 Jan 28. Aliment Pharmacol Ther. 2011. PMID: 21272047 Clinical Trial.
Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies.
Laine L, Katz PO, Johnson DA, Ibegbu I, Goldstein MJ, Chou C, Rossiter G, Lu Y. Laine L, et al. Among authors: rossiter g. Aliment Pharmacol Ther. 2011 Jan;33(2):203-12. doi: 10.1111/j.1365-2036.2010.04516.x. Epub 2010 Nov 30. Aliment Pharmacol Ther. 2011. PMID: 21114792 Clinical Trial.
Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease.
Monteleone G, Di Sabatino A, Ardizzone S, Pallone F, Usiskin K, Zhan X, Rossiter G, Neurath MF. Monteleone G, et al. Among authors: rossiter g. Aliment Pharmacol Ther. 2016 Mar;43(6):717-24. doi: 10.1111/apt.13526. Epub 2016 Jan 13. Aliment Pharmacol Ther. 2016. PMID: 26766141 Free PMC article. Clinical Trial.
Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study.
Sands BE, Feagan BG, Sandborn WJ, Schreiber S, Peyrin-Biroulet L, Frédéric Colombel J, Rossiter G, Usiskin K, Ather S, Zhan X, D'Haens G. Sands BE, et al. Among authors: rossiter g. Am J Gastroenterol. 2020 May;115(5):738-745. doi: 10.14309/ajg.0000000000000493. Am J Gastroenterol. 2020. PMID: 31850931 Clinical Trial.
Pharmacokinetics, Safety and Efficacy of Intravenous Vedolizumab in Paediatric Patients with Ulcerative Colitis or Crohn's Disease: Results from the Phase 2 HUBBLE Study.
Hyams JS, Turner D, Cohen SA, Szakos E, Kowalska-Duplaga K, Ruemmele F, Croft NM, Korczowski B, Lawrence P, Bhatia S, Kadali H, Chen C, Sun W, Rosario M, Kabilan S, Treem W, Rossiter G, Lirio RA. Hyams JS, et al. Among authors: rossiter g. J Crohns Colitis. 2022 Aug 30;16(8):1243-1254. doi: 10.1093/ecco-jcc/jjac036. J Crohns Colitis. 2022. PMID: 35301512 Free PMC article. Clinical Trial.
20 results